Document is current
Any future updates will be listed below
-
Authors
Lehenbauer, Katy S.
Nelson, Adam J.
Nodari, Savina
Sverdlov, Aaron L.
Harrington, Josephine
- License Information
-
More Information
Article History
Received: 10 June 2025
Revised: 13 October 2025
Accepted: 14 October 2025
First Online: 10 December 2025
Declarations
:
: AN has served as a consultant or as a speaker for Amgen, Boehringer Ingelheim, Eli Lilly, GSK, Novartis, Novo Nordisk, Pfizer and VAXXINITY. SN has received grants and/or speakers’ fees from Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, AMGEN, Menarini. AS has received grants and/or speakers’ fees and/or advisory board fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Galaxo Smith Kline, Janssen, Novartis, Novo Nordisk and RACE Oncology. He is supported by the National Heart Foundation of Australia Future Leader Fellowship (Award ID: 106025). JH has served as a consultant for Novo Nordisk.
: The authors declare no competing interests.
